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Background/Aims: Identi®cation of epitopes recognized by cytotoxic T lymphocytes (CTL) in hepatitis C virus (HCV)
proteins is of importance because they can be used for vaccination, treatment of infection or monitoring of immune
responses. Our purpose was to characterize new CTL epitopes in HCV structural proteins.
Methods: Peptides were synthesized and tested in HLA-A2 binding assays. Binder peptides were used to stimulate
peripheral blood mononuclear cells from HCV1 patients and controls, and activity measured in chromium release and
ELISPOT assays.
Results: Twenty binder peptides were found, and stimulation of HCV1 patient cells with nine peptides showing high
binding ability led to the growth of CD81 CTL recognizing peptide E2(614-622) in association with HLA-A2. Peptide
E2(614-622) was recognized by 30% of HLA-A21 patients with chronic HCV infection, but no responses were observed
in control groups. Five peptides derived from region E2(614-622) from 26 different viral isolates bound to HLA-A2
molecules, and all of them but one, containing Phe at position 622, were recognized by E2(614-622) speci®c CTL.
Conclusions: These results show that peptide E2(614-622) belongs to a highly conserved region of HCV E2, and might
be a good candidate to induce anti-HCV CTL responses in HLA-A21 subjects.
q 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatitis C virus (HCV) is a single stranded RNA virus
responsible for the majority of non-A non-B hepatitis [1].
Infection with HCV frequently evolves to chronicity, and
ultimately to cirrhosis and hepatocellular carcinoma [2].
After infection, patients elicit a wide range of antibodies
against viral proteins [3], which do not seem to be relevant
to clear infection. CD41 T-cell responses are also elicited
[4±10], although they are very weak or undetectable in
chronically infected patients. As in other viral infections,
CD81 cytotoxic T lymphocytes (CTL) have been detected
in HCV patients [11±17], and recent reports show their
importance in viral clearance in the acute phase of the
disease [18] and in HCV-exposed seronegative donors
[19,20]. CTL usually eliminate infected cells after recogni-
tion of viral antigens presented as short peptides in the HLA
molecules. These peptides are produced after processing of
viral proteins and they are presented by HLA molecules on
the cell surface [21]. The use of synthetic peptides has
allowed the characterization of these epitopes recognized
by CTL. These peptides usually contain certain amino
acids at some positions called anchor positions that de®ne
sequence patterns or motifs [22]. By using these HLA bind-
ing motifs, several CTL epitopes from HCV antigens have
been synthesized and tested [13,14,23±25]. These peptides
have ®rst been tested in binding assays and binder peptides
used to stimulate PBMC from HCV patients. However, not
all experimentally identi®ed peptides as CTL epitopes ful®l
these motifs [17], indicating that other peptides without the
common binding motif may exist and have not yet been
identi®ed. Identi®cation of CTL epitopes in the HCV
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proteins is of great importance, because they may be useful
for vaccine development, treat chronic infection or monitor
anti-HCV CTL immune responses.
In order to identify new CTL epitopes from HCV struc-
tural proteins we synthesized 9-mer peptides predicted as
binders to HLA-A2 by an algorithm, and overlapping 14-15-
mer peptides spanning almost the entire structural region.
We show below that binding to HLA-A2, one of the more
common HLA molecules, can be detected using both types
of peptides. Moreover, in vitro stimulation of cells from
HCV infected patients allowed us to identify CTL activity
against peptide E2(614-622), not previously characterized
as CTL epitope. These ®ndings are discussed in more detail
below.
2. Materials and methods
2.1. Synthetic peptides
Peptides were prepared manually as described [26]. Purity of the peptides
was always above 80% as judged by HPLC. Nine-mer peptides were
selected using an algorithm developed in our laboratory based on published
data [22]. This algorithm searches for peptides containing the HLA-A2
binding motif.
2.2. Cells
Cell lines T2 (gift of Dr Jay A. Berzofsky (NIH, Bethesda, USA)), JY
(HLA-A2.1, B7, Cw7), kindly gift of Dr Andreas Cerny (Bern, Switzer-
land), and BE (HLA-A24/26, B27/44), generated in our laboratory, were
maintained in complete medium (CM; RPMI containing 10% foetal bovine
serum (FBS), 4 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomy-
cin and 50 mM 2-mercaptoethanol).
2.3. HCV patients
Anti-HCV immune response was studied in 25 patients with chronic
hepatitis C (13 HLA-A21 and 12 HLA-A22). They had anti HCV-speci®c
antibodies and were HCV RNA positive by PCR. HLA-A2 typing was done
by using the anti-HLA-A2 BB7.2 monoclonal antibody (ATCC, Manassas,
VA). Twelve healthy seronegative HLA-A21 individuals were included as
controls. This study was approved by the institution's human research
committee and informed consent was obtained from the individuals.
2.4. Binding assays
Peptide binding to HLA-A2 molecules was measured using the T2
mutant cell line according to a protocol previously described [27]. Brie¯y,
T2 cells were incubated overnight in 96-well plates with peptide (100 mM).
Next day cells were washed and incubated with anti-HLA-A2 BB7.2 anti-
body and FITC-labelled goat anti mouse Ig. HLA-A2 expression was
measured by ¯ow cytometry, and quanti®ed as ¯uorescence index (FI)
according to the formula: FI (mean ¯uorescence with peptide - mean
¯uorescence without peptide)/ mean ¯uorescence without peptide.
2.5. CTL lines generation
CTL lines were generated as previously described [27]. PBMC (2 £ 106
cells) were stimulated in 1 ml in 24-well plates with 4 £ 106 autologous
cells pulsed for 3 h with 10 mM peptide or peptide mixtures in CM. After 3
days, CM with IL-2 (10 U/ml) was added to each well and the cells were
further expanded on day six with IL-2 containing medium. T cells (2 £ 106/
well) were stimulated every ten days with 4 £ 106 peptide pulsed irradiated
(3000 rads) autologous PBMC and expanded in IL-2 containing medium.
2.6. Cytotoxicity assay
CTL activity was measured using a 4-h assay with 51Cr-labeled target
cells. Autologous Concanavaline A-stimulated blasts or EBV-transformed
B cell lines JY and BE were used as targets.
2.7. Intracellular cytokine detection
T cells (105) were incubated in 96-well plates for 5 h at 378C with JY
cells (104) with or without peptide, in the presence of 10 U/ml IL-2 and
monensin (GolgiStopw; Pharmingen, San Diego, CA) according to manu-
facturer's instructions. After this period, cells were washed and stained with
PE-labeled anti-CD8 antibodies. Cells were ®xed and permeabilized with
Cyto®x/Cytopermw (Pharmingen), stained with FITC-labeled anti-IFN-g
antibodies and analyzed by ¯ow cytometry on a FACScan.
2.8. ELISPOT assay
Analysis of anti-peptide immune response in the different groups of
individuals was carried out by using an IFN-g-based ELISPOT assay
(Mabtech, Sweden) according to manufacturer's instructions. Brie¯y, 96-
well nitrocellulose-backed plates (MultiScreen-HA; Millipore, Bedford,
MA) were coated with capture antibody overnight at 48C. Next day, 105
CD81 puri®ed cells and 5 £ 104 mitomycin C-treated T2 cells were
cultured in triplicate wells. Peptide was added in some wells at 50 mM.
After 40 h of culture at 378C and 5% CO2, wells were washed and incubated
with detection antibody for 3 h at room temperature. After 1.5 h of incuba-
tion with Streptavidin-AP, plates were washed and colour reaction was
developed by adding BCIP/NBT substrate solution (BioRad, Hercules,
CA). Reaction was stopped after 30 min with distilled water, and spot
forming cells were counted. Responses were considered positive when
the number of spots per well were at least twice that in control wells.
2.9. HCV sequences
Sequences used to synthesize peptide variants of the CTL epitope studied
were collected from the literature. Sequences belonged to genotypes 1a, 1b,
2a and 2b (7, 15, 2 and 2 sequences, respectively). Gene Bank accession
numbers for these sequences were the following: M62321, M67463,
M62382, X53134, D16699, X53133, D10664, D90208, D11168/D01171,
D11355/D01172, M58335, M84754, D10750, D13558/D01217, L02836,
D90077/M57581, X61591, X61593, X61592, X61594, X61595, M86766,
D00944, D10075/6, D01221 and D10077/8.
3. Results
3.1. Binding of peptides from HCV structural proteins to
HLA-A2 molecules
In order to identify HLA-A2 binding peptides from HCV
structural proteins that could be potential CTL epitopes, we
used an algorithm that predicts peptide binding and synthe-
sized thirty two 9-mer peptides. Binding of these 9-mer
peptides to HLA-A2 was measured using T2 cells. Four
peptides from core, 2 from E1 and 3 from E2 showed
some degree of binding to HLA-A2 (Table 1). To study if
other peptides not predicted by algorithms could bind to
HLA-A2, we measured binding using 117 overlapping
peptides from HCV proteins: 39 fourteen-mer peptides
encompassing core protein, 36 ®fteen-mer peptides encom-
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passing E1 and 42 ®fteen-mer peptides encompassing 220
N-terminal amino acids from E2. This allowed us to use
peptides spanning all the possible 8-10-mer peptides
encompassed by HCV structural proteins. Three peptides
from core, three form E1 and ®ve from E2 proteins showed
positive results in binding assays, although they had lower
binding ability (as expressed by Fluorescence Index) than 9-
mer peptides (Table 1).
3.2. Growth of CTL lines from an HCV1 patient PBMC by
stimulation with binder peptides
CTL epitope character of the best binder peptides was
tested by in vitro stimulation of PBMC from an HCV1
HLA-A21 patient with these peptides. Two peptide pools
were used: pool #1, containing peptides c(132-140), c(168-
176), c(178-191), E1(285-293) and E2(614-622), and pool
#2, containing peptides E1(317-331), E1(322-336), E2(424-
438) and E2(684-692). After three stimulation cycles, cells
stimulated with peptide pool #1 had speci®c lytic activity
against peptide pulsed target cells, whereas cells stimulated
with pool #2 did not show any activity (Fig. 1A). When CTL
speci®c for pool #1 where tested against target cells pulsed
with individual peptides, only those pulsed with E2(614-
622) were lysed. This shows that CTL activity is due to
E2(614-622) only (Fig. 1B). In vitro priming of naive
CTL was discarded because a similar protocol did not
yield any activity when used with PBMC from four HLA-
A21 HCV seronegative donors (Fig. 1C).
Experiments using HLA-A21 and HLA-A2- target cells
showed that HLA-A2 was the molecule presenting E2(614-
622) to CTL (Fig. 2A). The phenotype of CTL was assessed
by ¯ow cytometry using an intracellular cytokine detection
assay, showing that CD81 cells are the main population
producing IFN-g after peptide stimulation. (Fig. 2B,C).
To study whether responses against peptides other than
E2(614-622) may co-exist but were masked by competition
for HLA-A2, responses against individual peptides were
tested by using an IFN-g-based ELISPOT assay. These
experiments showed that E2(614-622) was recognized by
the highest number of cells (Fig. 3), con®rming its immu-
nodominant role in the peptide pool. Moreover, weaker
responses against c(132-140) and E1(285-293) were also
detected.
3.3. Recognition of peptide E2(614-622) by patients with
chronic hepatitis C
After characterizing the presence of CTL speci®c for
E2(614-622) in a particular patient, it was important to
know the prevalence of the response to this peptide in
chronic HCV infection. Thus, we studied this response in
a group of 13 HLA-A21 patients with chronic hepatitis C by
using the IFN-g-based ELISPOT assay, that would also
provide data on precursor cell frequency. When CD81
cells from HLA-A21 patients were stimulated with peptide
E2(614-622), speci®c responses were detected in 30% of
them (Fig. 4A). We studied a group of HLA-A22 patients
with chronic hepatitis C and a group of healthy HLA-A21
seronegative individuals as controls. In none of these groups
we obtained a positive response (Fig. 4B,C), showing that
recognition of epitope E2(614-622) is speci®c of HLA-A21
subjects, and that response to this peptide is induced by viral
infection.
3.4. HLA binding and CTL recognition of sequences from
region E2(614-622) present in other viral isolates
A characteristic feature of HCV is the great variability
present among the different viral isolates [28], particularly
in envelope proteins. This variability has been interpreted
by several authors as a viral strategy to avoid immune
responses [29±32]. We analyzed region E2(614-622) in 26
viral isolates belonging to genotypes 1a, 1b, 2a and 2b
(Table 2). As it can be seen, only changes at position 622
(amino acid 9 of the peptide) were found. Most of the
sequences (18 out of 26) had V at position 9, as the peptide
used to stimulate the CTL. Four other amino acids were
found at this position, I, L, F and A, in 4, 2, 1 and 1 viral
isolates, respectively. Position 9 has been described as one
of the important anchor positions for peptide binding to
HLA-A2. Thus, these changes may affect peptide binding
and concomitantly CTL recognition. In order to study these
possibilities, we synthesized peptides containing these
substitutions and measured their ability to bind to HLA-
A2. Peptides E2(614-622) (with V at position 9) and
E2(614-622)I have the same degree of binding, E2(614-
622)L and E2(614-622)A have slightly less binding ability,
whereas E2(614-622)F needs higher peptide concentrations
to reach the same levels of binding (Fig. 5A). We also tested
the peptides in a CTL assay, to study the effect of these
mutations on CTL recognition. This experiment showed
that peptides with V, I, L or A at position 9 were almost
equally recognized by the CTL line thus induced (Fig. 5B).
However, peptide E2(614-622)F was poorly recognized,
showing a low activity only at the highest peptide concen-
tration. These results were con®rmed by independent
experiments done with a different CTL line raised also
against E2(614-622)V (data not shown).
4. Discussion
CTL are important effector cells in the control of many
viral diseases [33,34]. In the case of HCV infection, many
individuals become chronically infected despite the
presence of CTL. Although this may argue against the
role of CTL in the control of HCV infection, recent reports
show the importance of CTL in the ®nal outcome of the
infection [18,35], in the protection of individuals in contact
with HCV patients [19,20] or in patients clearing HCV after
a -IFN treatment [36]. Thus, strategies aimed to stimulate
CTL responses would be of great importance. For this
reason, identi®cation of relevant CTL epitopes from
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constant regions of HCV proteins is of paramount impor-
tance. CTL epitopes must bind to HLA molecules, thus, as a
®rst approach, we identi®ed peptides able to bind to HLA-
A2. Two strategies have been used to identify binder
peptides, synthesis of 9-mer peptides having a potential
HLA-A2 binding motif and synthesis of overlapping 14-
15-mer peptides. Both methods have proven useful for the
detection of binder peptides, but higher binding ability was
usually found for 9-mer peptides. This is probably due to
their ability to bind directly to HLA molecules. Most of the
14-15-mer binder peptides contained the binding motif,
although some of them, like E2(449-463) or E2(474-488)
did not contain any putative binding motif. Thus, we favour
the use of binding algorithms to detect binder peptides, but
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Fig. 2. (A) Characterization of the HLA molecule presenting peptide
E2(614-622) to CTL. JY cells (HLA-A21) and BE cells (HLA-A2-) were
used as targets. (B-C) Phenotype of CTL recognizing peptide E2(614-
622). T cells were incubated with HLA-A21 JY cells in the absence (B)
or in the presence (C) of E2(614-622), and stained with PE-labeled anti-
CD8 and FITC-labeled anti-g-IFN antibodies to analyze the phenotype
of peptide-speci®c T cells by ¯ow cytometry.
Fig. 1. (A) CTL activity of cells from an HLA-A21 HCV patient stimu-
lated with HLA-A2 binding peptides: pool #1 (peptides c(132-140),
c(168-176), c(178-191), E1(285-293) and E2(614-622)) and pool #2
(peptides E1(317-331), E1(322-336), E2(424-438) and E2(684-692)).
Results shown represent the difference in speci®c lysis between peptide
pulsed and unpulsed target cells. (B) Characterization of peptides
within pool #1 recognized by CTL. (C) CTL activity against E2(614-
622) obtained in four HCV HLA-A21 seronegative donors.
this strategy could be complemented by using also overlap-
ping 14-15-mers.
In order to identify new CTL epitopes, peptides with the
highest ability to bind to HLA-A2 were used to stimulate
PBMC from a patient chronically infected by HCV. These
experiments led to the growth of CTL lines speci®c for
E2(614-622). This peptide was recognized by CD81 CTL
in an HLA-A2 restricted manner. When peptides were
tested individually using CD81 cells from the same patient
by using an ELISPOT assay, the strongest IFN-g production
was induced by peptide E2(614-122). Although competition
for HLA-A2 may prevent detection of responses against
other peptides in chromium release assays, the low number
of precursor cells seems to be the main reason to explain this
phenomenon. Although we have only detected strong
responses against E2(614-622), one can not rule out the
possibility that some of the binder peptides used in the
present study, and not characterized as CTL epitopes,
might be able to stimulate CTL in other patients.
Analysis of the prevalence of the response to this peptide
in a wider group of patients with chronic hepatitis C showed
that 30% of them recognized the peptide. The number of
E2(614-622)-speci®c precursor cells in those patients with
positive responses was about 10±30/105 CD81 cells. In
these cases, persistence of viral replication in the presence
of CTL might be due to the low number of cells. Detection
of CTL responses against E2(614-622) by chromium release
assays required at least three in vitro stimulation cycles, and
reactivity against c(132-140) and E1(285-293) could be
detected only by ELISPOT, reinforcing the idea that their
number is indeed very low.
Sequence variability is a characteristic of HCV that may
have important implications for the development of a
protective immune response. Mutations in some immuno-
genic regions have been described, allowing the emergence
of escape mutants both at the B- and T-cell level [29±
32,37]. The use of epitopes belonging to immunologically
conserved regions is thus important [24]. Variability in
region E2(614-622) was localized at position 622, position
9 of the peptide sequence. Because this position plays the
role of an anchor to HLA-A2, modi®cation of this residue
may affect peptide-HLA binding and CTL recognition.
HLA-A2 usually allows the binding of peptides with
aliphatic residues at position 9 [22]. In this case, most of
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Table 2
Sequence of peptides from region E2(614-622) belonging to different
viral isolates
Peptide sequencea Number of isolates
RLWHYPCTV 18
RLWHYPCTI 4
RLWHYPCTL 2
RLWHYPCTA 1
RLWHYPCTF 1
a Variable residues are shown in bold.
Fig. 3. Recognition of HLA-A2 binder peptides by CD81 puri®ed cells
by ELISPOT. CD81 cells were incubated with T2 cells with or without
peptides (50 mM) in plates coated with anti IFN-g antibodies. Then,
spots were detected as described in Materials and Methods and
counted.
Fig. 4. Recognition of E2(614-622) peptide by CD81 cells by ELISPOT.
(A) HLA-A21 patients with chronic hepatitis C, (B) HLA-A2- patients
with chronic hepatitis C and (C) HLA-A21 healthy individuals.
Patients labelled with (*) represent positive responses.
the mutations found at this position presented amino acids
of this type. Thus, only substitution by F at position 622
had an important effect in binding and, as a consequence,
in CTL recognition. In the other viral isolates, although
they present mutations at this position, these mutations
did not affect binding to HLA-A2 and CTL recognition.
This means that most of the mutations in this position
could be considered immunologically silent. As F is only
present in 1 out of 26 sequences studied, from an immu-
nological point of view, E2(614-622) could be considered
as a conserved epitope.
In summary, peptide E2(614-622) has been characterized
as a new CTL epitope in HLA-A21 chronically infected
patients. This peptide belongs to a region which is very
well preserved with respect to CTL recognition, suggesting
the potential use of this epitope in strategies aiming at
enhancing anti-HCV cell immunity.
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